Bill Gates and Amazon founder Jeff Bezos—the two richest men in the world—are joining to back efforts to innovate new ways to diagnose and track Alzheimer’s disease. The support of two will help push forward efforts by the “venture philanthropy” project of the Alzheimer’s Drug Discovery Foundation (ADDF).
In the near future, ADDF is expected to name its first grantees, and is currently in the process of receiving applications for a second round of grants it is awarding, which focus on fast-tracking digital tools for Alzheimer’s and related dementias. Having launched last July, the diagnostic accelerator plans to deliver about $35 million grants over the next three years. The grants will be used to help fund the development of new clinical biomarkers and tests related to the study of Alzheimer’s.
Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer’s. ADDF follows a venture philanthropy model, funding breakthrough research in academia and the biotech industry.
This was reported by Fierce Biotech on April 3, 2019.
Contact Information: Alzheimer’s Drug Discovery Foundation, 57 West 57th Street, Suite 904, New York, New York 10019; (212) 901-8000; Website: www.alzdiscovery.org